Rani Therapeutics (NASDAQ:RANI – Get Free Report) and AquaBounty Technologies (NASDAQ:AQB – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Volatility and Risk
Rani Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, AquaBounty Technologies has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Rani Therapeutics and AquaBounty Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rani Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
| AquaBounty Technologies | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares Rani Therapeutics and AquaBounty Technologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rani Therapeutics | $1.63 million | 74.00 | -$29.67 million | ($0.27) | -3.20 |
| AquaBounty Technologies | $2.47 million | 2.40 | -$18.49 million | ($0.82) | -1.40 |
AquaBounty Technologies has higher revenue and earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than AquaBounty Technologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Rani Therapeutics and AquaBounty Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rani Therapeutics | N/A | -104.60% | -65.17% |
| AquaBounty Technologies | N/A | -147.07% | -28.73% |
Institutional & Insider Ownership
30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Rani Therapeutics beats AquaBounty Technologies on 9 of the 14 factors compared between the two stocks.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
About AquaBounty Technologies
AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
